siRNA-mediated simultaneous downregulation of uPA and its receptor inhibits angiogenesis and invasiveness triggering apoptosis in breast cancer cells

International Journal of Oncology

Volumn 28, Issue 4, 2006, Pages 831-839

  Subramanian, Ramesh ^a   Gondi, Christopher S ^a   Lakka, Sajani S ^a   Jutla, Aman ^a   Rao, Jasti S ^a,b  

^a Department of Cancer Biology and Pharmacology   (United States)

^b UNIVERSITY OF ILLINOIS   (United States)

Author keywords

Angiogenesis; Breast cancer cells; Invasion; uPA; uPAR

Indexed keywords

CELL SURFACE RECEPTOR; PLASMINOGEN ACTIVATOR, UROKINASE RECEPTORS; SMALL INTERFERING RNA; UROKINASE;

ANGIOGENESIS; APOPTOSIS; ARTICLE; BREAST TUMOR; CANCER INVASION; CELL CULTURE; CELL MOTION; CULTURE MEDIUM; DOWN REGULATION; DRUG EFFECT; ENDOTHELIUM CELL; GENE VECTOR; GENETIC TRANSFECTION; GENETICS; HUMAN; METABOLISM; PATHOLOGY; PHYSIOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TUMOR CELL LINE; WESTERN BLOTTING;

APOPTOSIS; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; CELLS, CULTURED; CULTURE MEDIA, CONDITIONED; DOWN-REGULATION; ENDOTHELIAL CELLS; GENETIC VECTORS; HUMANS; NEOPLASM INVASIVENESS; NEOVASCULARIZATION, PHYSIOLOGIC; RECEPTORS, CELL SURFACE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; RNA, SMALL INTERFERING; TRANSFECTION; URINARY PLASMINOGEN ACTIVATOR;

EID: 33744725239     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.28.4.831     Document Type: Article

References (52)

1. Symes K and Mercola M: Embryonic mesoderm cells spread in response to platelet-derived growth factor and signaling by phosphatidylinositol 3-kinase. Proc Natl Acad Sci USA 93: 9641-9644, 1996.
2. Blasi F: uPA, uPAR, PAI-1: key intersection of proteolytic, adhesive and chemotactic highways? Immunol Today 18: 415-417, 1997.
3. Leirisalo-Repo M: The present knowledge of the inflammatory process and the inflammatory mediators. Pharmacol Toxicol 75 (Suppl 2): 1-3, 1994.
4. Camussi G, Montrucchio G, Lupia E, Soldi R, Comoglio PM and Bussolino F: Angiogenesis induced in vivo by hepatocyte growth factor is mediated by platelet-activating factor synthesis from macrophages. J Immunol 158: 1302-1309, 1997. (Pubitemid 127469955)
5. Kim HJ, Ingbar DH and Henke CA: Integrin mediation of type II cell adherence to provisional matrix proteins. Am J Physiol 271: L277-L286, 1996.
6. Aznavoorian S, Murphy AN, Stetler-Stevenson WG and Liotta LA: Molecular aspects of tumor cell invasion and metastasis. Cancer 71: 1368-1383, 1993.
7. Sato H, Takino T, Okada Y, Cao J, Shinagawa A, Yamamoto E and Seiki M: A matrix metalloproteinase expressed on the surface of invasive tumour cells. Nature 370: 61-65, 1994.
8. Stetler-Stevenson WG, Aznavoorian S and Liotta LA: Tumor cell interactions with the extracellular matrix during invasion and metastasis. Annu Rev Cell Biol 9: 541-573, 1993. (Pubitemid 2021155)
9. Vassalli JD and Pepper MS: Tumour biology. Membrane proteases in focus. Nature 370: 14-15, 1994.
10. Mazar AP: The urokinase plasminogen activator receptor (uPAR) as a target for the diagnosis and therapy of cancer. Anticancer Drugs 12: 387-400, 2001.
11. Ossowski L and Aguirre-Ghiso JA: Urokinase receptor and integrin partnership: coordination of signaling for cell adhesion, migration and growth. Curr Opin Cell Biol 12: 613-620, 2000.
12. Preissner KT, Nawroth PP and Kanse SM: Vascular protease receptors: integrating haemostasis and endothelial cell functions. J Pathol 190: 360-372, 2000.
13. Dano K, Romer J, Nielsen BS, Bjorn S , Pyke C, Rygaard J and Lund LR: Cancer invasion and tissue remodeling - cooperation of protease systems and cell types. APMIS 107: 120-127, 1999.
14. Mustjoki S, Alitalo R, Stephens RW and Vaheri A: Plasminogen activation in human leukemia and in normal hematopoietic cells. APMIS 107: 144-149, 1999.
15. Yu W, Kim J and Ossowski L: Reduction in surface urokinase receptor forces malignant cells into a protracted state of dormancy. J Cell Biol 137: 767-777, 1997.
16. Moller LB: Structure and function of the urokinase receptor. Blood Coagul Fibrinolysis 4: 293-303, 1993.
17. Stahl A and Mueller BM: Melanoma cell migration on vitronectin: regulation by components of the plasminogen activation system. Int J Cancer 71: 116-122, 1997.
18. Wei Y, Lukashev M, Simon DI, Bodary SC, Rosenberg S, Doyle MV and Chapman HA: Regulation of integrin function by the urokinase receptor. Science 273: 1551-1555, 1996. (Pubitemid 26301666)
19. Burgering BM and Bos JL: Regulation of Ras-mediated signalling: more than one way to skin a cat. Trends Biochem Sci 20: 18-22, 1995.
20. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K and Tuschl T: Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411: 494-498, 2001.
21. Zamore PD: RNA interference: listening to the sound of silence. Nat Struct Biol 8: 746-750, 2001.
22. Lakka SS, Gondi CS, Yanamandra N, Olivero WC, Dinh DH, Gujrati M and Rao JS: Inhibition of cathepsin B and MMP-9 gene expression in glioblastoma cell line via RNA interference reduces tumor cell invasion, tumor growth and angiogenesis. Oncogene 23: 4681-4689, 2004.
23. Ma Z, Webb DJ, Jo M and Gonias SL: Endogenously produced urokinase-type plasminogen activator is a major determinant of the basal level of activated ERK/MAP kinase and prevents apoptosis in MDA-MB-231 breast cancer cells. J Cell Sci 114: 3387-3396, 2001.
24. Mohan PM, Lakka SS, Mohanam S, Kin Y, Sawaya R, Kyritsis AP, Nicolson GL and Rao JS: Downregulation of the urokinase-type plasminogen activator receptor through inhibition of translation by antisense oligonucleotide suppresses invasion of human glioblastoma cells. Clin Exp Metastasis 17: 617-621, 1999.
25. Mohanam S, Sawaya R, McCutcheon I, Ali-Osman F, Boyd D and Rao JS: Modulation of in vitro invasion of human glioblastoma cells by urokinase-type plasminogen activator receptor antibody. Cancer Res 53: 4143-4147, 1993.
26. Mohan PM, Chintala SK, Mohanam S, Gladson CL, Kim ES, Gokaslan ZL, Lakka SS, Roth JA, Fang B, Sawaya R, Kyritsis AP and Rao JS: Adenovirus-mediated delivery of antisense gene to urokinase-type plasminogen activator receptor suppresses glioma invasion and tumor growth. Cancer Res 59: 3369-3373, 1999.
27. Guo Y, Higazi AA, Arakelian A, Sachais BS, Cines D, Goldfarb RH, Jones TR, Kwaan H, Mazar AP and Rabbani SA: A peptide derived from the nonreceptor binding region of urokinase plasminogen activator (uPA) inhibits tumor progression and angiogenesis and induces tumor cell death in vivo. FASEB J 14: 1400-1410, 2000.
28. Huang S, New L, Pan Z, Han J and Nemerow GR: Urokinase plasminogen activator/urokinase-specific surface receptor expression and matrix invasion by breast cancer cells requires constitutive p38alpha mitogen-activated protein kinase activity. J Biol Chem 275: 12266-12272, 2000.
29. Bertrand JR, Pottier M, Vekris A, Opolon P, Maksimenko A and Malvy C: Comparison of antisense oligonucleotides and siRNAs in cell culture and in vivo. Biochem Biophys Res Commun 296: 1000-1004, 2002.
30. Stark JJ, Dillman RO, Schulof R, Wiemann MC, Barth NM, Honeycutt PJ and Soori G: Interferon-alpha and chemohormonal therapy for patients with advanced melanoma: final results of a phase I-II study of the Cancer Biotherapy Research Group and the Mid-Atlantic Oncology Program. Cancer 82: 1677-1681, 1998.
31. Li H, Lu H, Griscelli F, Opolon P, Sun LQ, Ragot T, Legrand Y, Belin D, Soria J, Soria C, Perricaudet M and Yeh P: Adenovirus-mediated delivery of a uPA/uPAR antagonist suppresses angiogenesis-dependent tumor growth and dissemination in mice. Gene Ther 5: 1105-1113, 1998.
32. Min HY, Doyle LV, Vitt CR, Zandonella CL, Shuman MA, Stratton-Thomas JR and Rosenberg S: Urokinase receptor antagonists inhibit angiogenesis and primary tumor growth in syngeneic mice. Cancer Res 56: 2428-2433, 1996.
33. Busso N, Masur SK, Lazega D, Waxman S and Ossowski L: Induction of cell migration by pro-urokinase binding to its receptor: possible mechanism for signal transduction in human epithelial cells. J Cell Biol 126: 259-270, 1994.
34. Fazioli F, Resnati M, Sidenius N, Higashimoto Y, Appella E and Blasi F: A urokinase-sensitive region of the human urokinase receptor is responsible for its chemotactic activity. EMBO J 16: 7279-7286, 1997.
35. Fibbi G, Ziche M, Morbidelli L, Magnelli L and Del Rosso M: Interaction of urokinase with specific receptors stimulates mobilization of bovine adrenal capillary endothelial cells. Exp Cell Res 179: 385-395, 1988.
36. Nguyen DH, Hussaini IM and Gonias SL: Binding of urokinase-type plasminogen activator to its receptor in MCF-7 cells activates extracellular signal-regulated kinase 1 and 2 which is required for increased cellular motility. J Biol Chem 273: 8502-8507, 1998.
37. Resnati M, Guttinger M, Valcamonica S, Sidenius N, Blasi F and Fazioli F: Proteolytic cleavage of the urokinase receptor substitutes for the agonist-induced chemotactic effect. EMBO J 15: 1572-1582, 1996.
38. Sato Y and Rifkin DB: Autocrine activities of basic fibroblast growth factor: regulation of endothelial cell movement, plasminogen activator synthesis, and DNA synthesis. J Cell Biol 107: 1199-1205, 1988.
39. Sato Y, Tsuboi R, Lyons R, Moses H and Rifkin DB: Characterization of the activation of latent TGF-beta by co-cultures of endothelial cells and pericytes or smooth muscle cells: a self-regulating system. J Cell Biol 111: 757-763, 1990.
40. Sidenius N and Blasi F: The urokinase plasminogen activator system in cancer: recent advances and implication for prognosis and therapy. Cancer Metastasis Rev 22: 205-222, 2003.
41. Chiaradonna F, Fontana L, Iavarone C, Carriero MV, Scholz G, Barone MV and Stoppelli MP: Urokinase receptor-dependent and -independent p56/59(hck) activation state is a molecular switch between myelomonocytic cell motility and adherence. EMBO J 18: 3013-3023, 1999.
42. Fazioli F and Blasi F: Urokinase-type plasminogen activator and its receptor: new targets for anti-metastatic therapy? Trends Pharmacol Sci 15: 25-29, 1994.
43. Aguirre Ghiso JA, Kovalski K and Ossowski L: Tumor dormancy induced by downregulation of urokinase receptor in human carcinoma involves integrin and MAPK signaling. J Cell Biol 147: 89-104, 1999.
44. Liu D, Aguirre Ghiso JA, Estrada Y and Ossowski L: EGFR is a transducer of the urokinase receptor initiated signal that is required for in vivo growth of a human carcinoma. Cancer Cell 1: 445-457, 2002.
45. Tang H, Kerins, DM Hao, Q, Inagami T and Vaughan DE: The urokinase-type plasminogen activator receptor mediates tyrosine phosphorylation of focal adhesion proteins and activation of mitogen-activated protein kinase in cultured endothelial cells. J Biol Chem 273: 18268-18272, 1998.
46. Rabbani SA, Gladu J, Mazar AP, Henkin J and Goltzman D: Induction in human osteoblastic cells (SaOS2) of the early response genes fos, jun, and myc by the amino terminal fragment (ATF) of urokinase. J Cell Physiol 172: 137-145, 1997.
47. Kjoller L and Hall A: Rac mediates cytoskeletal rearrangements and increased cell motility induced by urokinase-type plasminogen activator receptor binding to vitronectin. J Cell Biol 152: 1145-1157, 2001.
48. Bonni A, Brunet A, West AE, Datta SR, Takasu MA and Greenberg ME: Cell survival promoted by the Ras-MAPK signaling pathway by transcription-dependent and -independent mechanisms. Science 286: 1358-1362, 1999.
49. Guillonneau X, Bryckaert M, Launay-Longo C, Courtois Y and Mascarelli F: Endogenous FGF1-induced activation and synthesis of extracellular signal-regulated kinase 2 reduce cell apoptosis in retinal-pigmented epithelial cells. J Biol Chem 273: 22367-22373, 1998.
50. Xia Z, Dickens M, Raingeaud J, Davis RJ and Greenberg ME: Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science 270: 1326-1331, 1995.
51. Zou H, Henzel WJ, Liu X, Lutschg A and Wang X: Apaf-1, a human protein homologous to C. elegans CED-4, participates in cytochrome c-dependent activation of caspase-3. Cell 90: 405-413, 1997.
52. Cecconi F, Alvarez-Bolado G, Meyer BI, Roth KA and Gruss P: Apaf1 (CED-4 homolog) regulates programmed cell death in mammalian development. Cell 94: 727-737, 1998.